Skip to main content
Top
Published in: BMC Medicine 1/2019

Open Access 01-12-2019 | Antibiotic | Opinion

Optimising trial designs to identify appropriate antibiotic treatment durations

Authors: Koen B. Pouwels, Mo Yin, Christopher C. Butler, Ben S. Cooper, Sarah Wordsworth, A. Sarah Walker, Julie V. Robotham

Published in: BMC Medicine | Issue 1/2019

Login to get access

Abstract

Background

For many infectious conditions, the optimal antibiotic course length remains unclear. The estimation of course length must consider the important trade-off between maximising short- and long-term efficacy and minimising antibiotic resistance and toxicity.

Main body

Evidence on optimal treatment durations should come from randomised controlled trials. However, most antibiotic randomised controlled trials compare two arbitrarily chosen durations. We argue that alternative trial designs, which allow allocation of patients to multiple different treatment durations, are needed to better identify optimal antibiotic durations. There are important considerations when deciding which design is most useful in identifying optimal treatment durations, including the ability to model the duration–response relationship (or duration–response ‘curve’), the risk of allocation concealment bias, statistical efficiency, the possibility to rapidly drop arms that are clearly inferior, and the possibility of modelling the trade-off between multiple competing outcomes.

Conclusion

Multi-arm designs modelling duration–response curves with the possibility to drop inferior arms during the trial could provide more information about the optimal duration of antibiotic therapies than traditional head-to-head comparisons of limited numbers of durations, while minimising the probability of assigning trial participants to an ineffective treatment regimen.
Literature
1.
go back to reference de Kraker MEA, Jarlier V, Monen JCM, Heuer OE, van de Sande N, Grundmann H. The changing epidemiology of bacteraemias in Europe: trends from the European antimicrobial resistance surveillance system. Clin Microbiol Infect. 2013;19:860–8.CrossRef de Kraker MEA, Jarlier V, Monen JCM, Heuer OE, van de Sande N, Grundmann H. The changing epidemiology of bacteraemias in Europe: trends from the European antimicrobial resistance surveillance system. Clin Microbiol Infect. 2013;19:860–8.CrossRef
2.
go back to reference Whittles L, White P, Paul J, Didelot X. Epidemiological trends of antibiotic resistant gonorrhoea in the United Kingdom. Antibiotics. 2018;7(3);60.CrossRef Whittles L, White P, Paul J, Didelot X. Epidemiological trends of antibiotic resistant gonorrhoea in the United Kingdom. Antibiotics. 2018;7(3);60.CrossRef
3.
go back to reference Shrestha P, Cooper BS, Coast J, Oppong R, Do Thi Thuy N, Phodha T, et al. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use. Antimicrob Resist Infect Control. 2018;7:98.CrossRef Shrestha P, Cooper BS, Coast J, Oppong R, Do Thi Thuy N, Phodha T, et al. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use. Antimicrob Resist Infect Control. 2018;7:98.CrossRef
4.
go back to reference Naylor NR, Atun R, Zhu N, Kulasabanathan K, Silva S, Chatterjee A, et al. Estimating the burden of antimicrobial resistance: a systematic literature review. Antimicrob Resist Infect Control. 2018;7:58.CrossRef Naylor NR, Atun R, Zhu N, Kulasabanathan K, Silva S, Chatterjee A, et al. Estimating the burden of antimicrobial resistance: a systematic literature review. Antimicrob Resist Infect Control. 2018;7:58.CrossRef
6.
go back to reference Chatterjee A, Modarai M, Naylor NR, Boyd SE, Atun R, Barlow J, et al. Quantifying drivers of antibiotic resistance in humans: a systematic review. Lancet Infect Dis. 2018;18:e368–78.CrossRef Chatterjee A, Modarai M, Naylor NR, Boyd SE, Atun R, Barlow J, et al. Quantifying drivers of antibiotic resistance in humans: a systematic review. Lancet Infect Dis. 2018;18:e368–78.CrossRef
7.
go back to reference Pouwels KB, Dolk FCK, Smith DRM, Robotham JV, Smieszek T. Actual versus ‘ideal’ antibiotic prescribing for common conditions in English primary care. J Antimicrob Chemother. 2018;73(Suppl 2):19–26.CrossRef Pouwels KB, Dolk FCK, Smith DRM, Robotham JV, Smieszek T. Actual versus ‘ideal’ antibiotic prescribing for common conditions in English primary care. J Antimicrob Chemother. 2018;73(Suppl 2):19–26.CrossRef
8.
go back to reference Smieszek T, Pouwels KB, Dolk FCK, Smith DRM, Hopkins S, Sharland M, et al. Potential for reducing inappropriate antibiotic prescribing in English primary care. J Antimicrob Chemother. 2018;73(Suppl 2):ii36–43.CrossRef Smieszek T, Pouwels KB, Dolk FCK, Smith DRM, Hopkins S, Sharland M, et al. Potential for reducing inappropriate antibiotic prescribing in English primary care. J Antimicrob Chemother. 2018;73(Suppl 2):ii36–43.CrossRef
9.
go back to reference Pouwels KB, Freeman R, Muller-Pebody B, Rooney G, Henderson KL, Robotham JV, et al. Association between use of different antibiotics and trimethoprim resistance: going beyond the obvious crude association. J Antimicrob Chemother. 2018;73:1700–7.CrossRef Pouwels KB, Freeman R, Muller-Pebody B, Rooney G, Henderson KL, Robotham JV, et al. Association between use of different antibiotics and trimethoprim resistance: going beyond the obvious crude association. J Antimicrob Chemother. 2018;73:1700–7.CrossRef
10.
go back to reference Pouwels KB, Muller-Pebody B, Smieszek T, Hopkins S, Robotham JV. Selection and co-selection of antibiotic resistances among Escherichia coli by antibiotic use in primary care: an ecological analysis. BioRxiv. 2019;573360. https://doi.org/10.1101/573360. Pouwels KB, Muller-Pebody B, Smieszek T, Hopkins S, Robotham JV. Selection and co-selection of antibiotic resistances among Escherichia coli by antibiotic use in primary care: an ecological analysis. BioRxiv. 2019;573360. https://​doi.​org/​10.​1101/​573360.
11.
go back to reference Dawson-Hahn EE, Mickan S, Onakpoya I, Roberts N, Kronman M, Butler CC, et al. Short-course versus long-course oral antibiotic treatment for infections treated in outpatient settings: a review of systematic reviews. Fam Pract. 2017;34:511–9.CrossRef Dawson-Hahn EE, Mickan S, Onakpoya I, Roberts N, Kronman M, Butler CC, et al. Short-course versus long-course oral antibiotic treatment for infections treated in outpatient settings: a review of systematic reviews. Fam Pract. 2017;34:511–9.CrossRef
12.
go back to reference Onakpoya IJ, Walker AS, Tan PS, Spencer EA, Gbinigie OA, Cook J, et al. Overview of systematic reviews assessing the evidence for shorter versus longer duration antibiotic treatment for bacterial infections in secondary care. PLoS One. 2018;13:e0194858.CrossRef Onakpoya IJ, Walker AS, Tan PS, Spencer EA, Gbinigie OA, Cook J, et al. Overview of systematic reviews assessing the evidence for shorter versus longer duration antibiotic treatment for bacterial infections in secondary care. PLoS One. 2018;13:e0194858.CrossRef
13.
go back to reference King LM, Sanchez GV, Bartoces M, Hicks LA, Fleming-Dutra KE. Antibiotic therapy duration in US adults with sinusitis. JAMA Intern Med. 2018;178:992–4.CrossRef King LM, Sanchez GV, Bartoces M, Hicks LA, Fleming-Dutra KE. Antibiotic therapy duration in US adults with sinusitis. JAMA Intern Med. 2018;178:992–4.CrossRef
14.
go back to reference Pouwels KB, Hopkins S, Llewelyn M, Walker AS, McNulty CAM, Robotham JV. Antibiotic therapy duration for common infections in English primary care: a cross-sectional analysis and comparison with guidelines. BMJ. 2019;364:l440.CrossRef Pouwels KB, Hopkins S, Llewelyn M, Walker AS, McNulty CAM, Robotham JV. Antibiotic therapy duration for common infections in English primary care: a cross-sectional analysis and comparison with guidelines. BMJ. 2019;364:l440.CrossRef
15.
go back to reference Spellberg B. The new antibiotic mantra – “shorter is better”. JAMA Intern Med. 2016;176:1254–5.CrossRef Spellberg B. The new antibiotic mantra – “shorter is better”. JAMA Intern Med. 2016;176:1254–5.CrossRef
16.
go back to reference Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J, Murphy D. Trends of outpatient prescription drug utilization in US children, 2002–2010. Pediatrics. 2012;130:23–31.CrossRef Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J, Murphy D. Trends of outpatient prescription drug utilization in US children, 2002–2010. Pediatrics. 2012;130:23–31.CrossRef
17.
go back to reference Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015;314:1818–31.CrossRef Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015;314:1818–31.CrossRef
19.
go back to reference Charani E, Castro-Sanchez E, Sevdalis N, Kyratsis Y, Drumright L, Shah N, et al. Understanding the determinants of antimicrobial prescribing within hospitals: the role of “prescribing etiquette”. Clin Infect Dis. 2013;57:188–96.CrossRef Charani E, Castro-Sanchez E, Sevdalis N, Kyratsis Y, Drumright L, Shah N, et al. Understanding the determinants of antimicrobial prescribing within hospitals: the role of “prescribing etiquette”. Clin Infect Dis. 2013;57:188–96.CrossRef
22.
go back to reference Parmar MKB, Carpenter J, Sydes MR. More multiarm randomised trials of superiority are needed. Lancet. 2014;384:283–4.CrossRef Parmar MKB, Carpenter J, Sydes MR. More multiarm randomised trials of superiority are needed. Lancet. 2014;384:283–4.CrossRef
23.
go back to reference Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, et al. Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). Clin Infect Dis. 2015;61:800–6.CrossRef Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, et al. Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). Clin Infect Dis. 2015;61:800–6.CrossRef
24.
go back to reference Phillips PPJ, Morris TP, Walker AS. DOOR/RADAR: a gateway into the unknown? Clin Infect Dis. 2016;62:814–5.CrossRef Phillips PPJ, Morris TP, Walker AS. DOOR/RADAR: a gateway into the unknown? Clin Infect Dis. 2016;62:814–5.CrossRef
25.
go back to reference O’Riordan W, Tiffany C, Scangarella-Oman N, Perry C, Hossain M, Ashton T, et al. Efficacy, safety, and tolerability of gepotidacin (GSK2140944) in the treatment of patients with suspected or confirmed gram-positive acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2017;61:e02095–16.PubMedPubMedCentral O’Riordan W, Tiffany C, Scangarella-Oman N, Perry C, Hossain M, Ashton T, et al. Efficacy, safety, and tolerability of gepotidacin (GSK2140944) in the treatment of patients with suspected or confirmed gram-positive acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2017;61:e02095–16.PubMedPubMedCentral
26.
go back to reference Lee JJ, Chu CT. Bayesian clinical trials in action. Stat Med. 2012;31:2955–72.CrossRef Lee JJ, Chu CT. Bayesian clinical trials in action. Stat Med. 2012;31:2955–72.CrossRef
27.
go back to reference Berry SM, Carlin BP, Lee JJ, Muller P. Bayesian adaptive methods for clinical trials. Boca Raton: CRC Press; 2010.CrossRef Berry SM, Carlin BP, Lee JJ, Muller P. Bayesian adaptive methods for clinical trials. Boca Raton: CRC Press; 2010.CrossRef
28.
go back to reference Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol. 2012;9:199–207.CrossRef Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol. 2012;9:199–207.CrossRef
29.
go back to reference Quartagno M, Walker AS, Carpenter JR, Phillips PP, Parmar MK. Rethinking non-inferiority: a practical trial design for optimising treatment duration. Clin Trials. 2018;15:477–88.CrossRef Quartagno M, Walker AS, Carpenter JR, Phillips PP, Parmar MK. Rethinking non-inferiority: a practical trial design for optimising treatment duration. Clin Trials. 2018;15:477–88.CrossRef
31.
go back to reference Curtin F, Heritier S. The role of adaptive trial designs in drug development. Expert Rev Clin Pharmacol. 2017;10:727–36.CrossRef Curtin F, Heritier S. The role of adaptive trial designs in drug development. Expert Rev Clin Pharmacol. 2017;10:727–36.CrossRef
32.
go back to reference Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018;16:29.CrossRef Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018;16:29.CrossRef
33.
go back to reference Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA, et al. Acute stroke therapy by inhibition of neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke. 2003;34:2543–8.CrossRef Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA, et al. Acute stroke therapy by inhibition of neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke. 2003;34:2543–8.CrossRef
34.
go back to reference Faes C, Aerts M, Geys H, Molenberghs G. Model averaging using fractional polynomials to estimate a safe level of exposure. Risk Anal. 2007;27:111–23.CrossRef Faes C, Aerts M, Geys H, Molenberghs G. Model averaging using fractional polynomials to estimate a safe level of exposure. Risk Anal. 2007;27:111–23.CrossRef
35.
go back to reference Steel MFJ. Model averaging and its use in economics. arXiv.org. 2017;arXiv:1709.08221v2. Accessed 13 July 2018. Steel MFJ. Model averaging and its use in economics. arXiv.​org. 2017;arXiv:1709.08221v2. Accessed 13 July 2018.
36.
go back to reference Sydes MR, Parmar MK, Mason MD, Clarke NW, Amos C, Anderson J, et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012;13:168.CrossRef Sydes MR, Parmar MK, Mason MD, Clarke NW, Amos C, Anderson J, et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012;13:168.CrossRef
37.
go back to reference Cellamare M, Ventz S, Baudin E, Mitnick CD, Trippa L. A Bayesian response-adaptive trial in tuberculosis: the endTB trial. Clin Trials. 2017;14:17–28.CrossRef Cellamare M, Ventz S, Baudin E, Mitnick CD, Trippa L. A Bayesian response-adaptive trial in tuberculosis: the endTB trial. Clin Trials. 2017;14:17–28.CrossRef
38.
go back to reference Karrison TG, Huo D, Chappell R. A group sequential, response-adaptive design for randomized clinical trials. Control Clin Trials. 2003;24:506–22.CrossRef Karrison TG, Huo D, Chappell R. A group sequential, response-adaptive design for randomized clinical trials. Control Clin Trials. 2003;24:506–22.CrossRef
39.
go back to reference Hernán MA, Robins JM. Per-protocol analyses of pragmatic trials. N Engl J Med. 2017;377:1391–8.CrossRef Hernán MA, Robins JM. Per-protocol analyses of pragmatic trials. N Engl J Med. 2017;377:1391–8.CrossRef
40.
go back to reference Davies GR, Phillips PPJ, Jaki T. Adaptive clinical trials in tuberculosis: applications, challenges and solutions. Int J Tuberc Lung Dis. 2015;19:626–34.CrossRef Davies GR, Phillips PPJ, Jaki T. Adaptive clinical trials in tuberculosis: applications, challenges and solutions. Int J Tuberc Lung Dis. 2015;19:626–34.CrossRef
41.
go back to reference Lin J, Bunn V. Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials. Contemp Clin Trials. 2017;54:48–59.CrossRef Lin J, Bunn V. Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials. Contemp Clin Trials. 2017;54:48–59.CrossRef
42.
go back to reference Wason JMS, Trippa L. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. Stat Med. 2014;33:2206–21.CrossRef Wason JMS, Trippa L. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. Stat Med. 2014;33:2206–21.CrossRef
43.
go back to reference Coffey CS, Levin B, Clark C, Timmerman C, Wittes J, Gilbert P, et al. Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop. Clin Trials. 2012;9:671–80.CrossRef Coffey CS, Levin B, Clark C, Timmerman C, Wittes J, Gilbert P, et al. Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop. Clin Trials. 2012;9:671–80.CrossRef
44.
go back to reference Bornkamp B, Bretz F, Dmitrienko A, Enas G, Gaydos B, Hsu CH, et al. Innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat. 2007;17:965–95.CrossRef Bornkamp B, Bretz F, Dmitrienko A, Enas G, Gaydos B, Hsu CH, et al. Innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat. 2007;17:965–95.CrossRef
45.
go back to reference Gillespie D, Francis NA, Carrol ED, Thomas-Jones E, Butler CC, Hood K. Use of co-primary outcomes for trials of antimicrobial stewardship interventions. Lancet Infect Dis. 2018;18:595–7.CrossRef Gillespie D, Francis NA, Carrol ED, Thomas-Jones E, Butler CC, Hood K. Use of co-primary outcomes for trials of antimicrobial stewardship interventions. Lancet Infect Dis. 2018;18:595–7.CrossRef
46.
go back to reference Butler CC, Connor JT, Lewis RJ, Broglio K, Saville BR, Cook J, Van der Velden A, Verheij T. Answering patient-centred questions efficiently: response-adaptive platform trials in primary care. Br J Gen Pract. 2018;68:294–5.CrossRef Butler CC, Connor JT, Lewis RJ, Broglio K, Saville BR, Cook J, Van der Velden A, Verheij T. Answering patient-centred questions efficiently: response-adaptive platform trials in primary care. Br J Gen Pract. 2018;68:294–5.CrossRef
Metadata
Title
Optimising trial designs to identify appropriate antibiotic treatment durations
Authors
Koen B. Pouwels
Mo Yin
Christopher C. Butler
Ben S. Cooper
Sarah Wordsworth
A. Sarah Walker
Julie V. Robotham
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Antibiotic
Published in
BMC Medicine / Issue 1/2019
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-019-1348-z

Other articles of this Issue 1/2019

BMC Medicine 1/2019 Go to the issue